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possible role of highly activated 
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inmaculada casas4, Francisco pozo4, Francisco Reinoso-Barbero5, David Bueno3, 
Dolores corral3, Ana Méndez-echevarría1,2, Yasmina Mozo3 & cristina calvo1,2,6,7
infection is the leading cause of non-relapse-related mortality after allogeneic haematopoietic stem 
cell transplantation (HSCT). Altered functions of immune cells in nasal secretions may influence post 
HSCT susceptibility to viral respiratory infections. In this prospective study, we determined T and NK 
cell numbers together with NK activation status in nasopharyngeal aspirates (NPA) in HSCT recipients 
and healthy controls using multiparametric flow cytometry. We also determined by polymerase chain 
reaction (PCR) the presence of 16 respiratory viruses. Samples were collected pre-HSCT, at day 0, 
+10, +20 and +30 after HSCT. Peripheral blood (PB) was also analyzed to determine T and NK cell 
numbers. A total of 27 pediatric HSCT recipients were enrolled and 16 of them had at least one viral 
detection (60%). Rhinovirus was the most frequent pathogen (84% of positive NPAs). NPAs of patients 
contained fewer T and NK cells compared to healthy controls (p = 0.0132 and p = 0.120, respectively). 
Viral pcR + patients showed higher NK cell number in their NPAs. The activating receptors repertoire 
expressed by NK cells was also higher in NPA samples, especially NKp44 and NKp46. Our study supports 
nK cells relevance for the immune defense against respiratory viruses in HSct recipients.
Allogeneic haematopoietic stem cell transplant (HSCT) is a potentially curative procedure for a variety of pediat-
ric hematologic disorders. Post-transplant infections contribute significantly to the morbidity associated with this 
procedure. The ablation of HSCT recipient’s immune system by the conditioning regimen increases the suscep-
tibility to infections until they reach immune reconstitution from donor stem cells. The morbidity and mortality 
from respiratory viruses in immunocompromised patients, including those undergoing HSCT, is well established 
for respiratory syncytial virus (RSV)1–4, parainfluenza viruses (PIV)5,6, influenza viruses7,8, adenovirus9, and 
human metapneumovirus (HMPV)4,10. Recent data suggest that common human coronaviruses (HCoV) are also 
associated with significant mortality, similar to that seen with RSV, PIV and influenza11. There is less information 
regarding infections caused by human rhinoviruses (HRV) and human bocavirus (HBoV)12,13.
Natural Killer (NK) cells in the nasal secretions are a first line of defense against respiratory viruses both in 
healthy individuals and in those undergoing HSCT. They have a protective role against many viral infections com-
monly encountered after HSCT, including herpes simplex virus, varicella-zoster virus, cytomegalovirus and influ-
enza virus as well as some bacterial infections14–16. NK cells play important roles in the host’s immune defense 
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through the production of cytotoxic granules containing molecules such as perforins and granzymes that lyse 
infected cells. Other important features of NK cells are the production of cytokines including interferons, their 
enhancement of local immune responses by directly acting on target cells, and their role in the recruitment and 
activation of other immune cells, including T cells and macrophages17.
NK cells recognize virally infected cells through the integration of signaling from activating and inhibitory 
germ line encoded receptors on the NK cell surface17. Membrane bound Killer-cell Activation Receptors (KARs) 
work together with inhibitory Killer Immunoglobulin-like Receptors (KIRs), in order to regulate the NK cells 
functions on infected or transformed cells. The interaction between the KIR family on NK cells and HLA Class I 
molecules results in inhibitory signals. KARs, like the natural cytotoxicity receptors (NCRs), comprising NKp30, 
NKp46, and NKp44 are key receptors in the recognition and elimination of virally infected and tumor cells18,19.
Because immune cells in the nasal mucosa can control and regulate viral infections via killing infected res-
piratory epithelial cells, low numbers of NK and or T cells in the nasopharyngeal aspirates (NPAs) of HSCT 
pediatric recipients could be associated with an increased susceptibility to viral respiratory infections. Although 
blood immune reconstitution after an HSCT has been widely studied20–26, very little is known about the immune 
reconstitution in HSCT recipients’ mucosa. In the present study, our goals were: 1) to determine NK and T cell 
numbers in the nasal passages of HSCT recipients; 2) to determine the activation phenotype of NPAs’ NK cells 
using multiparametric flow cytometry; 3) to determine the presence and functional profile of these cells within 
the context of a viral infection; and 4) to assess the effects of viral infections on nasal immune reconstitution.
Materials and Methods
Study participants. Prospective study including patients under 18 years of age who received allogenic 
HSCT at La Paz University Hospital (Madrid, Spain), from January 2017 to June 2018. Exclusion criteria included 
chronic lung disease prior to HSCT. HSCT was performed according to current centre protocols, using bone 
marrow or peripheral blood stem cells as haematopoietic stem cell source. Acute and chronic graft versus host 
disease (GVHD) were defined and graded as previously reported27,28.
Age- and sex-matched controls were recruited among healthy patients undergoing elective surgery. Cases 
and controls were also matched according to procedure date (HSCT and elective surgery, respectively) ± 1 week.
All research was performed in accordance to local regulations. Informed consent in accordance with the 
Declaration of Helsinki was obtained from the parents of all children. The study was approved by the Clinical 
Research Ethics Committee at La Paz University Hospital.
Study samples. Study samples were peripheral blood (PB) and NPAs that were collected prior to the condi-
tioning regimen and after HSCT at days 15 and 30 for PB mononuclear cells and before the conditioning regimen 
and at days 0, 10, 20 and 30 after HSCT for NPAs. The following tests were performed in each sample type:
•	 PB: total, T and NK cell counts.
•	 NPAs: total T and NK cell counts, natural cytotoxicity receptors, viral detection.
For NPA collection, 1 mL of 0.9% saline solution was instilled into each nostril and the nasopharynx was 
suctioned using a sterile catheter with a mucus trap. NPAs were not performed if the patient had active bleed-
ing or his platelet count was below 20.000/mm3. NPA samples containing blood were considered not valid and 
discarded. Each specimen was sent to the Respiratory Virus and Influenza Unit at the National Microbiology 
Center (ISCIII, Madrid, Spain) for viral analysis and to the Translational Research in Paediatric Oncology, 
Hematopoietic Transplantation & Cell Therapy Unit at La Paz Hospital Research Institute (Madrid, Spain) for 
flow cytometry assays. NPAs were processed within 24 hours after collection. In the control group, NPAs were 
collected on the day of surgery.
Viral detection by Rt-pcR. Upon reception of the samples, three aliquots were prepared and stored at 
−80 °C. Both the reception and the NPA sample processing areas are separated from those defined as working 
areas. Three independent RT-PCR assays were performed to detect sixteen respiratory viruses as previously pub-
lished by our group29–31. Influenza A, B and C viruses were detected by using previously described primer sets 
only to amplify influenza viruses in a multiplex PCR assay29. A second multiplex PCR was used to detect parain-
fluenza viruses 1 to 4, human coronaviruses 229E and OC43, enteroviruses and HRV30. Presence of RSV A and B 
types, HMPV, HBoV and adenoviruses was established using a third multiplex RT-nested PCR−BRQ method31.
Cell characterization by flow cytometry. For flow cytometry assays, NPA samples were filtered with a 
70 µm cell strainer (Falcon), centrifuged at 1400 rpm (5 min) and suspended in 100 µl of PBS. Total sample volume 
was acquired using a Navios flow cytometer (Beckman Coulter).
The total cell count per sample was determined. T cell (CD45+, CD3+ CD56−) and Natural killer (NK) 
cell (CD45+, CD56+, CD3−) populations were identified using the following labelled antibodies: CD45-FITC/
APCCy7 (clone 2D1, BD Pharmingen), CD56-APC (clone NCAM16.2, BD Pharmingen) and CD3-PECy7 (clone 
UCHT1, Biolegend). Fluorescent cell viability dye 7-AAD (BD Pharmingen) was used to exclude dead cells. 
FlowJo v10.0.7 software (TreeStar) was used for data analysis.
The expression of natural cytotoxicity receptors (NCRs), NKG2A and NKG2D receptors on NK cells sub-
population in NPA was evaluated with the following fluorochrome-conjugated antibodies: NKG2D CD314-PE 
(clone BAT221, MiltenyiBiotec); NKp46 CD335-FITC (clone 9E2, AbDSerotec); NKp44 CD-336-PE (clone 44, 
BD Pharmingen); NKp30 CD337-PE (clone REA823, MiltenyiBiotec); NKG2A-PE (clone 131411, R&D systems; 
T1, Biolegend).
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Statistical analysis. Values are expressed as percentages for discrete variables and as median and inter-
quartile range (IQR) for continuous variables. Comparisons between groups (controls and HSCT patients before 
conditioning, and patients with and without viral respiratory infections) were made using Mann-Whitney U test, 
and Fisher’s exact test) as appropriate. A value of P < 0.05 was considered statistically significant. All analyses 
were performed using the SPSS statistical software, version 21.0 (IBM Corp.).
Results
HSct recipients and control group characteristics. During the study period, 27 HSCT recipients were 
recruited. Their main characteristics are summarized in Table 1. The median age of patients was 7.7 years (IQR 
9.2).
All HSCT were allogenic. Twenty-five patients underwent HSCT for the first time (93%) and two received 
their second HSCT (7%).
Eighteen healthy children were included in the control group, 10 male (56%) and 8 female (44%), with a 
median age of 8.7 years (IQR 9). There were no significant differences regarding age and sex between HSCT 
recipients and healthy controls.
Viral infections. A total of 83 samples were collected from the 27 HSCT recipients, and 77 were valid for viral 
studies (median number of valid samples per patient: 3; IQR 2). Twenty-five samples (32%) were positive, and 16 
of 27 HSCT recipients (60%) had at least one viral detection. Among HSCT recipients with viral infection, the 
median number of positive samples per patient was 1 (IQR 1). HRV was isolated in 21 samples (84% of positive 
NPA) from 12 patients, followed by adenovirus and parainfluenza type 1 (two positive samples from two different 
patients each, 8%). There were no viral coinfections among HSCT recipients. Detailed information regarding 
positive samples is given in Table 2.
Infections caused by HRV were symptomatic in 2 of 12 patients (17%): one had low-grade fever and the 
other persistent rhinorrhea. Both patients with adenovirus infections had fever, mucositis and elevated levels 
of C-reactive protein (above 100 mg/L). Infections by parainfluenza type 1 virus were also symptomatic (one 
patient with fever and another with laryngitis and pneumonia). None of the patients required admission to the 
intensive care unit (ICU) nor died as a result of a viral infection. There were no differences regarding age between 
HSCT recipients with and without viral infections (median [IQR] 7.5 [8.8] and 6 [10.2] years of age, respectively, 
p = 0.94), but patients below two years of age tested positive more frequently (11/21 samples, 52% vs. 14/56, 25%, 
p = 0.03).
Age (years) 6 (9.8)














Bone marrow 14 (52)
Mobilized peripheral blood 13 (48)
Conditioning regimen
Reduced intensity 17 (63)
Myeloablative 10 (37)
GVHD prophylaxis* 25 (93)
In vivo: ATG/alemtuzumab 14 (52)
Ex vivo: T-celldepletion (CD45RA/ TCRαβ) 11 (41)
Table 1. Characteristics of haematopoietic stem cell transplantation recipients (n = 27). Data are n 
(%) or median (interquartile range) where appropriate. Abbreviations: HSCT, haematopoietic stem cell 
transplantation; PID, primary immunodeficiency; SAA, severe aplastic anemia; ALL, acute lymphoblastic 
leukaemia; AML, acute myeloid leukaemia; MDS, myelodysplastic syndrome; MRD, matched related donor; 
MMRD, mismatched related donor; MUD, matched unrelated donor; MMUD, mismatched unrelated donor; 
GVHD, graft versus host disease; ATG, anti-thymocyte globulin. *Two patients transplanted from HLA-
identical siblings received neither ATG nor T-cell depletion.
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A total of 17 samples from healthy controls were analyzed, and viruses were identified in 4 (24%): two sin-
gle infections (HRV and adenovirus) and two coinfections (HRV and HBoV, HRV and adenovirus) (Table 2). 
Controls with viral infections were younger, but this difference did not reach statistical significance (median 
[IQR] 4.1 [6.6] vs. 8.9 [8.5] years, p = 0.07). All infections were asymptomatic.
No significant differences were found regarding viral isolation rate between patients and healthy controls (32% 
and 24% of samples, respectively, p = 0.57).
NPA cellular composition of HSCT recipients. The NPAs of patients prior to HSCT conditioning con-
tained fewer T and NK cells as compared with healthy controls p = 0.0132 and p = 0.120, respectively (Fig. 1A). 
Additionally, PCR + patients prior to HSCT conditioning showed statistically significant higher numbers of NK 
cells in NPAs than PCR− patients (p = 0.006). Those differences were not observed in healthy controls or in the 
T cell populations isolated from NPAs.
We further analyzed T and NK cell kinetics after the HSCT. We observed an increase in T cells in the NPA 
samples at infusion day. This increase is reverted at day 10 post HSCT, when NPA cell counts reach levels similar 
to those observed prior to the HSCT. This effect was observed both in PCR+ and in PCR− patients (Fig. 1B and 
Suppl. Table 1). However, we did not observe that peak with NK cells. There were no differences regarding NPA T 
and NK cell counts over time in patients with and without respiratory infection.
pB cellular composition of HSct recipients. Prior to the HSCT, the initial T cell counts were higher in 
PCR+ patients than in PCR− patients (median, IQR 2014, 3677-1090 vs. 945, 1751-249 cells/µl, p = 0.07)) (Fig. 2 
and Suppl. Table 2). However, PCR + and PCR− patients had similar initial NK cells counts prior to the HCT 
(median, IQR 154, 225-61 vs. 111, 185-62 cells/µl). Median T cell counts decreased notably after the HSCT, both 
in PCR+ and PCR− patients and on day 30 post HSCT the numbers were still far from the initial values. This 





samples (%) Respiratory viruses (n°)
HSCT recipients
Day 7 20 9 (45) HRV (6), ADV (2), PIV (1)
Day 0 21 6 (29) HRV (6)
Day 10 15 3 (20) HRV (3)
Day 20 12 4 (33) HRV (4)
Day 30 6 3 (50) HRV (2), PIV (1)
After day 30 3 0
Healthy controls 17 4 (24) HRV (1), ADV (1), HRV + AV (1), HRV + HBoV (1)
Table 2. Samples with positive viral detection. Abbreviations: ADV, adenovirus; HBoV, human bocavirus; HRV, 
human rhinovirus; PIV, parainfluenza virus. *A total of five samples were not valid because they contained 
blood or because polymerase chain reaction was inhibited.
Figure 1. T and NK cells in nasopharyngeal aspirates (NPAs) of patients prior to the HSCT conditioning are 
reduced as compared to healthy controls and have similar post HSCT kinetics in patients with and without viral 
respiratory infection. (a) Total number of T (CD45+, CD3+ CD56−) and NK cells (CD45+, CD3-, CD56+) in 
NPA of healthy controls and patients prior to the HSCT conditioning was determined by multiparametric flow 
cytometry. (b) Number of T and NK cells in NPAs was also monitored for one month post HSCT.
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Natural cytotoxicity receptors (NCRs) expression in NPA’s NK cells. The NK cells found in the NPA 
samples had a highly activated status as determined by flow cytometry analysis (Fig. 3A). The percentage of NK 
cells expressing different activating receptors was higher in PCR + NPA samples than in PCR− samples for all 
the receptors analyzed, and especially significant for NKp44 and NKp46 receptors (Fig. 3B). The highly activated 
status was observed both in healthy donors and HSCT patients’ NPAs.
HSct recipient outcomes. The outcomes of HSCT recipients are summarized in Table 3. There were no 
significant differences according to the presence of viral infection. The number of T or NK cells in patients’ NPAs 
pre-, during- or after-HSCT was not correlated with a higher risk of GVHD, graft failure, ICU admission or death 
(Suppl. Tables 3 and 4).
Discussion
The nasal mucosa is the first place within the respiratory system to be exposed to inhaled viral pathogens. 
Therefore, nasal immune cells are likely to play an important role in early innate immune responses to those 
environmental factors, both in healthy individuals and in immunocompromised patients like HSCT recipients. 
NK cells are thought to play a particularly important role in this context, since they are able to influence both 
innate and adaptive immune responses32,33 and are the first lymphocyte subset to appear in PB after HSCT20–26. 
While macrophages and dendritic cells have been identified in the nasal submucosa34, and neutrophils have been 
identified in the nasal cavity35, the immune cells present in NPAs have not been fully characterized. To phenotype 
NPA cells, previous researchers have relied on cell differential analysis of cytocentrifuge slides stained with hae-
matoxylin and eosin. However, flow cytometry may be a superior method to fully characterize NPA immune cells 
since it allows for a precise quantification of cell populations as well as for phenotype studies, making it possible 
to determine the activation status of such specific cell populations.
Our study showed that HSCT patients, as expected -due to conditioning regimens and underlying disease- 
had fewer T and NK cells in their NPAs as compared to healthy controls. Interestingly, those patients exposed 
to viral pathogens showed statistically significant higher NK cell counts in their NPAs, which is in accordance 
with their role in the “front line” defense against viral infections. The phenotypes and functions of NK cells differ 
depending on the source organ or tissue36–38. Our current research further explores the particular phenotype of 
nasal NK cells, which show a higher activation status than those found in PB, comparing the results obtained in 
this study with previous publications from our group24. This was especially true for those individuals with positive 
viral detection in their nasal secretions. Okada et al. recently reported that NK cells found in the nasal passages 
of mice belong to the conventional NK cell linage and characteristically demonstrate an immature and activated 
phenotype39. Our results constitute the first evidence of such observations in humans.
In our study, we observed an unexpected T cells increase in NPAs on HSCT day 0 samples, despite condi-
tioning regimens. We attribute it to the fact that all NPA samples were collected in the morning, and almost all 
patients receiving non-manipulated grafts (60% of our cohort) had finished their infusions prior to NPA collec-
tion. Pre-transplant conditioning, such as high-dose chemotherapy is toxic to many cells and render the endothe-
lium vulnerable40 which could lead to increased T cells in NPA of many patients.
Natural killer cell activity is regulated through the balance of signals from inhibitory and activating recep-
tors. The natural cytotoxicity receptors (NCRs) NKp46 (NCR1), NKp44 (NCR2), and NKp30 (NCR3), as well as 
NKG2D, are the main activating receptors involved in mediating NK cell function in health and disease18,19. The 
Figure 2. T and NK cells in peripheral blood (PB) of HSCT recipients. Number of T (CD45+, CD3+ CD56-) 
and NK cells (CD45+, CD3−, CD56+) in PB of HSCT patients was determined by multiparametric flow 
cytometry. Differences in T and NK cells numbers in PB of patients with PCR− and PCR+ for respiratory virus 
are indicated (n = 18).
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most overexpressed activating receptors we found in NK cells of NPAs were NKp44 (NCR2) and NKp46 (NCR1). 
This is consistent with Shemer-Avni et al.’s findings41. In nasal lavage samples of patients infected with respiratory 
viruses, they found NKp46 as the most abundantly expressed NCR. However, in their RTqPCR analysis they 
detected no NKp44 expression and very little of NKp30. Altogether, our findings point to NKp44 as a key player 
in nasal mucosa elimination of virally infected cells by NK cells.
Conditioning regimens used for allogeneic HSCT, high dose chemotherapy and/or radiotherapy, induce 
serious damage in mucosal, humoral and cellular immune function. Moreover, those regimens can harm 
Figure 3. NK cells in NPAs have a high activating status especially in PCR+ samples. (a) One representative 
flow cytometry analysis of an HSCT recipient NPA. CD45+, CD3−, CD56− cells were analyzed for the 
indicated NCRs (red lines) and compared with fluorescence minus one controls (grey). (b) Percentage of NK 







Number of cases 27 16 11
Acute GVHD 11 (41)
7 (44) 4 (36) 1I-II 4 (15)
III-IV 7 (26)
Chronic GVHD 3 (11)




Graft failure 2 (7) 1 (6) 1 (9) 1
ICU admission 7 (26) 2 (12) 5 (45) 0.08
Death 7 (26) 3 (19) 4 (36) 0.391
Table 3. Outcomes of haematopoietic stem cell transplantation recipients. Data are n (%). Abbreviations: 
GVHD, graft versus host disease; ICU, intensive care unit.
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the host’s thymopoiesis resulting in further delayed immune recovery25,26. Collectively, these factors predis-
pose the host to a variety of infections. In fact, despite the routine use of prophylactic antimicrobials in the 
peri-transplant period42,43, infections occur is about 80–85% of HSCT recipients and are one of the leading causes 
of non-relapse-related mortality after allogeneic HSCT44,45.
More than half of the HSCT recipients included in our study presented a viral respiratory infection at some 
point. To date, most studies of these infections in pediatric HSCT recipients have focused on symptomatic indi-
viduals, reporting an incidence of 5–11%46–48. Asymptomatic respiratory infections in children undergoing HSCT 
have been barely studied. A prospective study of 33 patients detected respiratory viruses in 24% of them before 
HSCT, mainly HRV and adenovirus49. In our series, infections caused by HRV were the most common, and were 
not associated with increased morbidity. These findings are in concordance with those reported by Srinivasan et 
al. in children with cancer or post-HSCT and upper or lower respiratory infection13 and asymptomatic children 
before HSCT49. Other authors have reported implementing routine extensive pre-HSCT lung screening, includ-
ing bronchoalveolar lavage for the detection of viruses, bacteria and fungi. In that study, almost one third of 
asymptomatic patients had viral respiratory infections, mainly caused by rhinovirus, and none of these worsened 
during HSCT50. On the other hand, infections caused by adenovirus and parainfluenza virus were less frequent 
but more often symptomatic in our patients. Adenovirus has been described as a cause of lower respiratory tract 
infection with high mortality after HSCT in studies involving symptomatic children46,51. We did not find a cor-
relation between viral infection and HSCT outcomes, which could be caused by small sample size and low inci-
dence of symptomatic infection.
Important strengths of our study include its prospective design and the determination of number, activation 
phenotype and functional profile of NK cells together with respiratory virus detection, assessing HSCT recipients 
over time and comparing them with healthy controls. Potential limitations of our study relate to sample size and 
losses to follow-up. NPA cell counts have great variability so larger cohorts would be desirable to draw stronger 
conclusions. Many patients did not tolerate well NPAs and withdrew during the course of the study. The small 
number of patients further precluded correlation of viral detection and transplantation outcomes, and limits our 
ability to examine the implications of asymptomatic viral respiratory infections in HSCT recipients. NPAs were 
collected up to 30 days after HSCT, and some infections occurring later may have been missed. However, most 
respiratory viral infections in HSCT recipients occur soon after transplantation, and adverse clinical outcomes are 
more likely to occur in the same period46,51.
In conclusion, we provide data suggesting NK cells as major effectors in respiratory viral control in the nasal 
mucosa. We also characterized this NK cell population finding a highly activated phenotype compared with 
that of their PB counterparts. Further study of this unique mucosal immune cell population will be beneficial in 
assessing the effects of viral infections on upper respiratory immune responses in HSCT recipients as well as in 
healthy individuals.
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